ROSEMARY REARDON: Open Payments
NPI 1275614471 · PLYMOUTH, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,368 in 93 payments from 17 companies in 2025. Trend: 2023 $1,852 · 2024 $2,554 · 2025 $2,368
Food & beverage: $2,179Education: $189
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 8 | $356 |
| Galderma Laboratories, L.P. | 18 | $324 |
| GENZYME CORPORATION | 6 | $254 |
| ABBVIE INC. | 9 | $244 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 7 | $201 |
| Regeneron Healthcare Solutions, Inc. | 7 | $164 |
| Incyte Corporation | 7 | $162 |
| Amgen Inc. | 5 | $139 |
| LEO Pharma Inc. | 5 | $134 |
| Novartis Pharmaceuticals Corporation | 5 | $109 |
Products named: TREMFYA, DUPIXENT, NEMLUVIO, SKYRIZI, OPZELURA, Otezla, ILUMYA, COSENTYX.
Industry payments across MA — which companies pay providers there.
